NCT05209308View on ClinicalTrials.gov

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 22, 2022

Primary Completion Date

March 15, 2023

Study Completion Date

March 15, 2023

Conditions
CLL
Interventions
DRUG

Zandelisib

Zandelisib taken orally for 7 days of each 28 day cycle

DRUG

Rituximab

Rituximab IV for 6 cycles

DRUG

Venetoclax

Orally - Ramp up weeks 1-5

Trial Locations (4)

11794

Stony Brook University, Stony Brook

73104

OU Health Stephenson Cancer Center, Oklahoma City

99208

Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane

02215

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

MEI Pharma, Inc.

Collaborators (1)

Kyowa Kirin, Inc.
All Listed Sponsors
collaborator

Kyowa Kirin, Inc.

INDUSTRY

lead

MEI Pharma, Inc.

INDUSTRY

NCT05209308 - Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL | Biotech Hunter | Biotech Hunter